The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Bisphosphonate Drug Holiday & Hip Fracture Risk

Bisphosphonate Drug Holiday & Hip Fracture Risk

November 21, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting , investigators conducted a population-based cohort study of long-term bisphosphonate use in women to evaluate the hip fracture rate after a drug holiday.1

You Might Also Like
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
Also By This Author
  • Efficacy of Tocilizumab Monotherapy After Ultra-Short Glucocorticoid Administration in GCA

Researchers used Medicare data from 2006–2014 to identify women with medical and pharmacy coverage who initiated bisphosphonate therapy and were at least 80% adherent to that therapy for a minimum of three years (baseline) when follow-up began. Researchers calculated crude hip fracture rates for women who continued to receive bisphosphonates and for those who discontinued the treatment. The rates were calculated for time since discontinuing treatment (i.e., drug holiday length), extending up to three years.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study identified 156,236 women who were highly adherent, long-term users of bisphosphonates. The mean patient age was 78.5 (SD=7.5) years. Alendronate was the most commonly used bisphosphonate, with 72% of patents having used the agent and 52% having exclusively used it. Zoledronic acid was used by 16% of women, with 9% of women having exclusively used this agent. Thirteen percent of women (7,947) subsequently resumed bisphosphonate therapy.

During a median follow-up of two years, 40% of women discontinued using bisphosphonate treatment for at least six months (n=62,676). Thirteen percent of these women (n=7,947) restarted a bisphosphonate at a later date.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During follow-up, 3,745 hip fractures occurred. Current bisphosphonate users had the lowest rate of hip fracture (9.6% crude incidence per 1,000 person-years). Patients who had a longer drug holiday experienced higher rates of hip fracture. The longer the drug holiday, the higher the rate of hip fracture. Women who had a one to two year drug holiday had a 13.3% crude incidence of hip fracture per 1,000 person-years. Women who had a two to four year drug holiday had a 15.7% crude incidence of hip fracture per 1,000 person-years. Overall, 11% (n=16,904) of patients died during the study, with details not provided.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Curtis JR, Chen R, Li Z, et al. The impact of the duration of bisphosphonate drug holidays on hip fracture rates [abstract]. Arthritis Rheumatol. 2017; 69(suppl 10).

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: Bisphosphonate, bisphosphonates, drug holiday, Fractures, hip, hip fracture, hip fracture risk, Osteoporosis, osteoporosis treatments

You Might Also Like:
  • Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
  • Mediterranean Diet Tied to Lower Hip Fracture Risk

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)